Trial reportNutrients2018
Resveratrol in Patients with Minimal Hepatic Encephalopathy.
Trial report in Nutrients, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Effects of resveratrol supplementation on renal function in adults: a systematic review and dose-response meta-analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Pooled it
- Resveratrol for the Management of Human Health: How Far Have We Come? A Systematic Review of Resveratrol Clinical Trials to Highlight Gaps and Opportunities.International journal of molecular sciences · 2024Pooled it
- Resveratrol and Depression in Animal Models: A Systematic Review of the Biological Mechanisms.Molecules (Basel, Switzerland) · 2018Pooled it
- Resveratrol protects against isoflurane-induced testicular injury: a stereological and molecular study in mice.Clinics (Sao Paulo, Brazil) · 2026Article
- Resveratrol as an Adjunct Antiviral Agent in Pediatric Viral Infections: A Review on Mechanistic Insights and Gut Microbiota Modulation.International journal of molecular sciences · 2025Review
- The Role of Various Types of Diets in the Treatments of Depressive Disorders.Medicina (Kaunas, Lithuania) · 2025Review
- Enhancing the Bioavailability of Resveratrol: Combine It, Derivatize It, or Encapsulate It?Pharmaceutics · 2024Review
- Targeting Neurological Disorders with Stilbenes: Bridging the Preclinical-Clinical Gap.International journal of biological sciences · 2024Review
- Hesperidin reduces depressive symptoms in post-coronary artery bypass graft patients with mild depression.Food science & nutrition · 2023Article
- Research on Mechanisms of Chinese Medicines in Prevention and Treatment of Postoperative Adhesion.Chinese journal of integrative medicine · 2023Review
- Curcumin-resveratrol nano-formulation counteracting hyperammonemia in rats.Metabolic brain disease · 2023Article
- Minimal Hepatic Encephalopathy Affects Daily Life of Cirrhotic Patients: A Viewpoint on Clinical Consequences and Therapeutic Opportunities.Journal of clinical medicine · 2022Review
- Resveratrol's neural protective effects for the injured embryoid body and cerebral organoid.BMC pharmacology & toxicology · 2022Article
- Therapeutic Applications of Resveratrol in Hepatic Encephalopathy through Its Regulation of the Microbiota, Brain Edema, and Inflammation.Journal of clinical medicine · 2021Review
- Ocoxin as a complement to first line treatments in cancer.International journal of medical sciences · 2021Review
- Additive Effect of Resveratrol on Astrocyte Swelling Post-exposure to Ammonia, Ischemia and Trauma In Vitro.Neurochemical research · 2020Article
- Resveratrol in Autism Spectrum Disorders: Behavioral and Molecular Effects.Antioxidants (Basel, Switzerland) · 2020Review
- Influence of Resveratrol on the Immune Response.Nutrients · 2019Review
- Nuclear Peroxisome Proliferator-Activated Receptors (PPARs) as Therapeutic Targets of Resveratrol for Autism Spectrum Disorder.International journal of molecular sciences · 2019Review
- Dietary Flavonoids Interaction with CREB-BDNF Pathway: An Unconventional Approach for Comprehensive Management of Epilepsy.Current neuropharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMinimal Hepatic Encephalopathy (MHE) is characterized by an impairment of social interaction, emotional behavior, sleep disorders, physical and mental symptoms, and diminished Quality of Life (QoL). The aim of our study is evaluating the potential liver health promoting a perspective of Resveratrol (RV) activities and evaluate whether RV treatment may improve health related quality of life (HRQL) and reduce depression and anxiety in patients with MHE.
methods
resultsIn the comparison between RV group and placebo group we observed a decrease in Back Depression Inventory (BDI) (
conclusionsResveratrol showed efficacy in the treatment of depression, anxiety, and ammonia serum levels, and improved the quality of life Of MHE patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.